WBP2NL

Across TCGA pan-cancer cohorts, WBP2NL Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated WBP2NL data layer compared with 21 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher WBP2NL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated WBP2NL expression acts as an unfavorable survival marker.

SKCM, READ, and GBM are the cancer types where WBP2NL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.518	0.790	<.001	33	view →
READ	OS	Median	All	0.287	0.823	.001	18	view →
GBM	OS	Median	All	0.062	0.413	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	All	0.390	0.727	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

WBP2NL–SKCM (OS)

Open the SKCM breakdown →